These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 11607819)

  • 1. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.
    Ayton PM; Cleary ML
    Oncogene; 2001 Sep; 20(40):5695-707. PubMed ID: 11607819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
    Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
    J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
    Sano K
    Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The small oligomerization domain of gephyrin converts MLL to an oncogene.
    Eguchi M; Eguchi-Ishimae M; Greaves M
    Blood; 2004 May; 103(10):3876-82. PubMed ID: 14751928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
    DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
    Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
    So CW; Cleary ML
    Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
    Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
    Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common mechanism for oncogenic activation of MLL by forkhead family proteins.
    So CW; Cleary ML
    Blood; 2003 Jan; 101(2):633-9. PubMed ID: 12393557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.
    García-Cuéllar MP; Zilles O; Schreiner SA; Birke M; Winkler TH; Slany RK
    Oncogene; 2001 Jan; 20(4):411-9. PubMed ID: 11313972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
    DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
    Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis.
    Daser A; Rabbitts TH
    Genes Dev; 2004 May; 18(9):965-74. PubMed ID: 15132992
    [No Abstract]   [Full Text] [Related]  

  • 12. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations.
    Drexler HG; Quentmeier H; MacLeod RA
    Leukemia; 2004 Feb; 18(2):227-32. PubMed ID: 14671638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
    Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
    PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein.
    Wechsler DS; Engstrom LD; Alexander BM; Motto DG; Roulston D
    Genes Chromosomes Cancer; 2003 Jan; 36(1):26-36. PubMed ID: 12461747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells.
    Joh T; Hosokawa Y; Suzuki R; Takahashi T; Seto M
    Oncogene; 1999 Jan; 18(4):1125-30. PubMed ID: 10023690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. t(10;11)-acute leukemias with MLL-AF10 and MLL-ABI1 chimeric transcripts: specific expression patterns of ABI1 gene in leukemia and solid tumor cell lines.
    Shibuya N; Taki T; Mugishima H; Chin M; Tsuchida M; Sako M; Kawa K; Ishii E; Miura I; Yanagisawa M; Hayashi Y
    Genes Chromosomes Cancer; 2001 Sep; 32(1):1-10. PubMed ID: 11477655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The leukemogenic fusion of MLL with ENL creates a novel transcriptional transactivator.
    Schreiner SA; García-Cuéllar MP; Fey GH; Slany RK
    Leukemia; 1999 Oct; 13(10):1525-33. PubMed ID: 10516753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
    Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.
    Joh T; Yamamoto K; Kagami Y; Kakuda H; Sato T; Yamamoto T; Takahashi T; Ueda R; Kaibuchi K; Seto M
    Oncogene; 1997 Oct; 15(14):1681-7. PubMed ID: 9349501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
    Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
    Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.